Perspective: A program to improve protein biomarker discovery for cancer

被引：116

作者：

Aebersold, R ^{[1
]}

Anderson, L ^{[1
]}

Caprioli, R ^{[1
]}

Druker, B ^{[1
]}

Hartwell, L ^{[1
]}

Smith, R ^{[1
]}

机构：

[1] Fred Hutchinson Canc Res Ctr, Seattle, WA 98109 USA

来源：

JOURNAL OF PROTEOME RESEARCH | 2005年 / 4卷 / 04期

关键词：

biomarker; cancer; discovery; research platform; informatics; reagents;

D O I：

10.1021/pr050027n

中图分类号：

Q5 [生物化学];

学科分类号：

071010 ; 081704 ;

摘要：

Biomarkers for cancer risk, early detection, prognosis, and therapeutic response promise to revolutionize cancer management. Protein biomarkers offer tremendous potential in this regard due to their great diversity and intimate involvement in physiology. An effective program to discover protein biomarkers using existing technology will require team science, an integrated informatics platform, identification and quantitation of candidate biomarkers in disease tissue, mouse models of disease, standardized reagents for analyzing candidate biomarkers in bodily fluids, and implementation of automation. Technology improvements for better fractionation of the proteome, selection of specific biomarkers from complex mixtures, and multiplexed assay of biomarkers would greatly enhance progress.

引用

收藏

页码：1104 / 1109

页数：6

相关论文

共 26 条

[1] The human plasma proteome - History, character, and diagnostic prospects [J].

Anderson, NL ;

Anderson, NG .

MOLECULAR & CELLULAR PROTEOMICS, 2002, 1 (11) :845-867

[2] Mass spectrometric quantitation of peptides and proteins using stable isotope standards and capture by anti-peptide antibodies (SISCAPA) [J].

Anderson, NL ;

Anderson, NG ;

Haines, LR ;

Hardie, DB ;

Olafson, RW ;

Pearson, TW .

JOURNAL OF PROTEOME RESEARCH, 2004, 3 (02) :235-244

[3] Future options with trastuzumab for primary systemic and adjuvant therapy [J].

Baselga, J ;

Gianni, L ;

Geyer, C ;

Perez, EA ;

Riva, A ;

Jackisch, C .

SEMINARS IN ONCOLOGY, 2004, 31 (05) :51-57

[4] 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: Clinical practice guidelines of the American Society of Clinical Oncology [J].

Bast, RC ;

Ravdin, P ;

Hayes, DF ;

Bates, S ;

Fritsche, H ;

Jessup, JM ;

Kemeny, N ;

Locker, GY ;

Mennel, RG ;

Somerfield, MR .

JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (06) :1865-1878

[5] Design and synthesis of visible isotope-coded affinity tags for the absolute quantification of specific proteins in complex mixtures [J].

Bottari, P ;

Aebersold, R ;

Turecek, F ;

Gelb, MH .

BIOCONJUGATE CHEMISTRY, 2004, 15 (02) :380-388

[6] Gene expression signature of fibroblast serum response predicts human cancer progression: Similarities between tumors and wounds [J].

Chang, HY ;

Sneddon, JB ;

Alizadeh, AA ;

Sood, R ;

West, RB ;

Montgomery, K ;

Chi, JT ;

van de Rijn, M ;

Botstein, D ;

Brown, PO .

PLOS BIOLOGY, 2004, 2 (02) :206-214

[7] Loss of IGF2 imprinting:: A potential marker of colorectal cancer risk [J].

Cui, HM ;

Cruz-Correa, M ;

Giardiello, FM ;

Hutcheon, DF ;

Kafonek, DR ;

Brandenburg, S ;

Wu, YQ ;

He, XB ;

Powe, NR ;

Feinberg, AP .

SCIENCE, 2003, 299 (5613) :1753-1755

[8] Delineation of prognostic biomarkers in prostate cancer [J].

Dhanasekaran, SM ;

Barrette, TR ;

Ghosh, D ;

Shah, R ;

Varambally, S ;

Kurachi, K ;

Pienta, KJ ;

Rubin, MA ;

Chinnaiyan, AM .

NATURE, 2001, 412 (6849) :822-826

[9] Imatinib as a paradigm of targeted therapies [J].

Druker, BJ .

ADVANCES IN CANCER RESEARCH, VOL 91, 2004, 91 :1-+

[10] The case for early detection [J].

Etzioni, R ;

Urban, N ;

Ramsey, S ;

McIntosh, M ;

Schwartz, S ;

Reid, B ;

Radich, J ;

Anderson, G ;

Hartwell, L .

NATURE REVIEWS CANCER, 2003, 3 (04) :243-252